Ypsomed expands to more countries
Following the successful and controlled launch of the mylife™ YpsoPump® during 2016 in Germany, the Netherlands and the UK, the Management of the Ypsomed Group has decided in favour of geographic expansion. In addition to the existing home markets such as France, Italy, Switzerland, Austria and Scandinavia, the innovative insulin pump is also to be launched in Belgium, Spain and India during 2017. The mylife™ YpsoPump® is already available in Czechia since January 2017, where the subsidiary was established at the end of 2016, mainly for its distribution.
Ypsomed CEO Simon Michel justifies the investment into geographic expansion as follows: "The introduction phase of the mylife™ YpsoPump® has shown that it meets the needs of many people with diabetes. Simplicity in training and in use gives many people a certain degree of freedom and independence in their daily therapy and considerably simplifies the process in the pump centres and physicians practices. Furthermore, the competitive situation in the market for insulin pumps is extremely dynamic. Due to this development we foresee excellent opportunities of growing successfully in this highly competitive market and to continue establishing ourselves as a diabetes specialist. All good reasons to exploit important and missing markets inside and outside Europe with additional investments."
The Ypsomed Group is a leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist with over 30 years' experience. As a leader in innovation and technology, Ypsomed is the preferred partner for pharmaceutical and biotech companies for the supply of pens, autoinjectors and infusion systems to administer liquid drugs. Ypsomed promotes and sells its product portfolio under the umbrella brands mylife Diabetescare directly to patients or through pharmacies and clinics and under YDS Ypsomed Delivery Systems as business-to-business to pharmaceutical companies. Ypsomed has its headquarters in Burgdorf, Switzerland, and operates a global network of manufacturing sites, subsidiaries and distributors. The Ypsomed Group employs almost 1'300 employees. Additional information are available under www.ypsomed.com.
Press releases you might also be interested in
Weitere Informationen zum Thema "Medizintechnik":
Künstliche Intelligenz optimiert das Mobilfunknetz
Das Mobilfunknetz, ein komplexes Konstrukt aus Mobilfunkstandorten und Netzelementen, sorgt dafür, dass Menschen jederzeit und überall miteinander telefonieren und ihre digitalen Anwendungen nutzen können. Die Instandhaltung, Überprüfung und Optimierung einer solch vielschichtigen Struktur erfordert jede Menge menschliches und technisches Know-how. Um komplexe Zusammenhänge im Mobilfunknetz noch besser zu verstehen, setzt Telefónica Deutschland seit einiger Zeit Algorithmen und Künstliche Intelligenz (KI) ein.Weiterlesen